Enhanced Antitumor Effect of the Combination of Bacille Calmette-Guérin and an Immune Checkpoint Inhibitor in Bladder Cancer-On-a-Chip
Tóm tắt
We upgraded preexisting bladder cancer-on-a-chip (BCOC) by adding T cells and evaluated the antitumor effect of a combination of intravesical Bacille Calmette-Guérin (BCG) and pembrolizumab. We fabricated bioprinted BCOC with microfluids, incorporating HT1376, MRC-5, HUVEC, THP-1 and Jurkat cells. We evaluated the effector-to-target cytotoxicity, cytokine, and cell viability in 2D culture, live/dead assay, migration assay, and cytokine assay in BCOC. Additionally, we evaluated the antitumor efficacy of the combination of BCG and pembrolizumab in an orthotopic mouse model. The combination group showed the most effective reduction compared to the control in 2D culture (100.0 ± 0.8% vs. 36.4 ± 0.8%, p < 0.001). In BCOC, cancer cell viabilities were decreased at 3 days in the BCG group (70.1 ± 9.8%, p = 0.013) and combination group (49.3 ± 8.1%, p < 0.001). The combination group showed the highest immune reaction in the cytokine assay (interferon-γ, p = 0.045; interleukin-6, p = 0.037) and migration assay (fold change 1.3 ± 0.1, p < 0.001), whereas in the in vivo model, it showed lower signal intensities from days 10 to 14 compared to that in the control group (p = 0.031 and p = 0.014, respectively). No significant weight changes were observed among the groups. We developed a 3D bioprinted BCOC via use of the monocytic THP-1 cells and Jurkat T cells to assess the efficacy of immunotherapy. The combination of BCG and pembrolizumab showed the best antitumor efficacy in BCOC and animal models.
Tài liệu tham khảo
Takeda, T., et al.: Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 73, 1318–1322 (2009). https://doi.org/10.1016/j.urology.2008.12.039
Patel, V.G., Oh, W.K., Galsky, M.D.: Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404–423 (2020). https://doi.org/10.3322/caac.21631
Balar, A.V., et al.: Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919–930 (2021). https://doi.org/10.1016/S1470-2045(21)00147-9
Lopez-Beltran, A., et al.: Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 13, 131 (2021). https://doi.org/10.3390/cancers13010131
Wei, S.C., Duffy, C.R., Allison, J.P.: Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 8, 1069–1086 (2018). https://doi.org/10.1158/2159-8290.CD-18-0367
Cerignoli, F., et al.: In vitro immunotherapy potency assays using real-time cell analysis. PLoS One 13, e0193498 (2018). https://doi.org/10.1371/journal.pone.0193498
Lee, S., Kim, J.H., Kang, S.J., Chang, I.H., Park, J.Y.: Customized multilayered tissue-on-a-chip (MToC) to simulate bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer treatment. BioChip J. 16, 67–81 (2022)
Kim, J.H., et al.: Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette-Guerin. Int J Mol Sci (2021). https://doi.org/10.3390/ijms22168887
van der Bruggen, P., et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991). https://doi.org/10.1126/science.1840703
McDermott, D.F., Atkins, M.B.: Interleukin-2 therapy of metastatic renal cell carcinoma—predictors of response. Semin. Oncol. 33, 583–587 (2006). https://doi.org/10.1053/j.seminoncol.2006.06.004
Leach, D.R., Krummel, M.F., Allison, J.P.: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996). https://doi.org/10.1126/science.271.5256.1734
Mansh, M.: Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J. Biol. Med. 84, 381–389 (2011)
Maia, M.C., Hansen, A.R.: A comprehensive review of immunotherapies in prostate cancer. Crit. Rev. Oncol. Hematol. 113, 292–303 (2017). https://doi.org/10.1016/j.critrevonc.2017.02.026
Choi, S.Y., Kim, S.J., Chi, B.H., Kwon, J.K., Chang, I.H.: Modulating the internalization of bacille Calmette-Guérin by cathelicidin in bladder cancer cells. Urology 85, 964.e7-e12 (2015). https://doi.org/10.1016/j.urology.2014.12.028
Fuge, O., Vasdev, N., Allchorne, P., Green, J.S.: Immunotherapy for bladder cancer. Res Rep Urol. 7, 65–79 (2015). https://doi.org/10.2147/RRU.S63447
Cheng, W., Fu, D., Xu, F., Zhang, Z.: Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis. 7, 2 (2018). https://doi.org/10.1038/s41389-017-0013-7
Jackson, A.M., et al.: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin. Exp. Immunol. 99, 369–375 (1995). https://doi.org/10.1111/j.1365-2249.1995.tb05560.x
Fuentes, L., Hernández, M., Fernández-Avilés, F.J., Crespo, M.S., Nieto, M.L.: Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ. Res. 91, 681–688 (2002). https://doi.org/10.1161/01.res.0000038341.34243.64
Song, M., et al.: Hsa_circ_0000652 aggravates inflammation by activation of macrophages and enhancement of OX40/OX40L interaction in ankylosing spondylitis. Front Cell Dev Biol. 9, 737599 (2021). https://doi.org/10.3389/fcell.2021.737599
F. Hoffmann-La Roche Ltd: Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer. GlobeNewswire; 2021. https://www.globenewswire.com/news-release/2021/03/08/2188308/0/en/Roche-provides-update-on-Tecentriq-US-indication-in-prior-platinum-treated-metastatic-bladder-cancer.html. Accessed 1 June 2022.
Kamat, A.M., et al.: KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 16, 507–516 (2020). https://doi.org/10.2217/fon-2019-0817
Feng, Z., Vuky, J.: Combination therapy with immune checkpoint inhibitors in urothelial carcinoma: current data and future outlook. Oncology (Williston Park) 35, 410–420 (2021). https://doi.org/10.46883/ONC.2021.3507.0410
Wang, Y., et al.: Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco. Targets. Ther. 11, 2891–2899 (2018). https://doi.org/10.2147/OTT.S165840
Chevalier, M.F., et al.: Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. Eur. Urol. 74, 540–544 (2018). https://doi.org/10.1016/j.eururo.2018.06.045